BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-1441@pharmaconomics
DTSTAMP:20260707T031034Z
DTSTART;VALUE=DATE:20260327
DTEND;VALUE=DATE:20260328
SUMMARY:IMMP PDUFA — eftilagimod alfa (efti)
DESCRIPTION:The FDA's approval decision on eftilagimod alfa (efti) for non-small cell lung cancer (1L NSCLC) is due Mar 27\, 2026. A green light opens the market\; a complete response letter (CRL) usually sinks the stock.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1506184/000119312526029877/d34373dex991.htm\n\nTrack it: https://pharmaconomics.com/e/1441
URL:https://pharmaconomics.com/e/1441
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:IMMP catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR